Current concepts for the combined treatment modality of ionizing radiation with anticancer agents

Current Pharmaceutical Design

Volumn 13, Issue 5, 2007, Pages 519-535

  Oehler, Christoph ^a   Dickinson, Daniel J ^a   Broggini Tenzer, Angela ^a   Hofstetter, Barbara ^a   Hollenstein, Andreas ^a   Riesterer, Oliver ^a   Vuong, Van ^a   Pruschy, Martin ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Angiogenesis; DNA repair; Hypoxia; Ionizing radiation; Radioresistance; Redistribution; Reoxygenation; Repopulation

Indexed keywords

2 (MORPHOLIN 4 YL) BENZO[H]CHROMEN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 N MORPHOLINE 8 DIBENZOTHIOPHENYLCHROMEN 4 ONE; 7 HYDROXYSTAUROSPORINE; AG 14361; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEP 3891; CISPLATIN; DNA; ENDOSTATIN; EPOTHILONE A; EPOTHILONE B; ETOPOSIDE; IC 86621; IMATINIB; IXABEPILONE; KU 55933; LISOFYLLINE; MITOMYCIN C; NU 7026; NU 7441; PACLITAXEL; PENTOXIFYLLINE; PROTEIN TYROSINE PHOSPHATASE; SB 218078; STI 517; SU 11752; TNP 40; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; WORTMANNIN;

ALOPECIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL STRESS; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; DRUG POTENTIATION; DRUG STRUCTURE; HELA CELL; HUMAN; IONIZING RADIATION; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIOBIOLOGY; RADIOSENSITIVITY; REOXYGENATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIATION, IONIZING;

EID: 33947607828     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780162935     Document Type: Review

References (193)

1. Bentzen SM. Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based. Radiother Oncol 2005; 77(3): 227-30.
2. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005; 6(2): 112-7.
3. Bernier J, Fuks Z. Advances in translational radiation oncology: from molecular signaling to cancer cure. Int J Radiat Oncol Biol Phys 2004; 58(2): 305-6.
4. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004; 4(9): 737-47.
5. Hall EJ. Radiobiology for the radiologist: Lippincott Williams and Wilkins; 2000.
6. Moshous D, Callebaut I, de Chasseval R, Corneo B, Cavazzana-Calvo M, Le Deist F, et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 2001; 105(2): 177-86.
7. Westphal CH, Hoyes KP, Canman CE, Huang X, Kastan MB, Hendry JH, et al. Loss of atm radiosensitizes multiple p53 null tissues. Cancer Res 1998; 58(24): 5637-9.
8. Undarmaa B, Kodama S, Suzuki Y, Niwa O, Watanabe M. X-ray-induced telomeric instability in Atm-deficient mouse cells. Biochem Biophys Res Commun 2004; 315(1): 51-8.
9. Hanson JR. The viridin family of steroidal antibiotics. Nat Prod Rep 1995; 12(4):381-4.
10. Hollick JJ, Golding BT, Hardcastle JR, Martin N, Richardson C, Rigoreau LJ, et al. 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK). Bioorg Med Chem Lett 2003; 13(18): 3083-6.
11. Hardcastle IR, Cockcroft X, Curtin NJ, El-Murr MD, Leahy JJ, Stockley M, et al. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem 2005; 48(24): 7829-46.
12. Griffin RJ, Fontana G, Golding BT, Guiard S, Hardcastle IR, Leahy JJ, et al. Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. J Med Chem 2005; 48(2): 569-85.
13. Kashishian A, Douangpanya H, Clark D, Schlachter ST, Eary CT, Schiro JG, et al. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther 2003; 2(12):1257-64.
14. Ismail IH, Martensson S, Moshinsky D, Rice A, Tang C, Howlett A, et al. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 2004; 23(4): 873-82.
15. Uhrhammer N, Fritz E, Boyden L, Meyn MS. Human fibroblasts transfected with an ATM antisense vector respond abnormally to ionizing radiation. Int J Mol Med 1999; 4(1): 43-7.
16. Guha C, Guha U, Tribius S, Alfieri A, Casper D, Chakravarty P, et al. Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors. Gene Ther 2000; 7(10): 852-8.
17. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003; 63 (7): 1550-4.
18. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64(24): 9152-9.
19. Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA, Camphausen K, et al. Gleevoc-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res 2003; 63(21): 7377-83.
20. Cowell IG, Durkacz BW, Tilby MJ. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated. Biochem Pharmacol 2005; 7(1-2):13-20.
21. Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 2003; 1(12): 913-20.
22. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434(7035): 913-7.
23. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917-21.
24. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 2003; 63(18): 6008-15.
25. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004; 23(44): 7322-9.
26. Walworth NC. Cell-cycle checkpoint kinases: checking in on the cell cycle. Curr Opin Cell Biol 2000; 12(6): 697-704.
27. Zhou BB, Elledge SJ. The DNA damage response: putting check-points in perspective. Nature 2000; 408(6811): 433-9.
28. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. Science 2002; 297(5581): 547-51.
29. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432(7015): 316-23.
30. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 2004; 3(8-9): 997-1007.
31. Rauth AM. Evidence for dark-reactivation of ultraviolet light damage in mouse L cells. Radiat Res 1967; 31(l): 121-38.
32. Waldren CA, Rasko I. Caffeine enhancement of X-ray killing in cultured human and rodent cells. Radiat Res 1978; 73(1): 95-110.
33. Timson J. Caffeine. Mutat Res 1977; 47(l): 1-52.
34. Busse PM, Bose SK, Jones RW, Tolmach IJ. The action of caffeine on X-irradiated HeLa cells. III. Enhancement of X-ray-induced killing during G2 arrest. Radiat Res 1978; 76(2): 292-307.
35. Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 1995; 55(8): 1649-54.
36. Russell KJ, Wiens LW, Demers GW, Galloway DA, Le T, Rice GC, et al. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int J Radiat Oncol Biol Phys 1996; 36(5): 1099-106.
37. Lock RB, Galperina OV, Feldhoff RC, Rhodes LJ. Concentration-dependent differences in the mechanisms by which caffeine potentiates etoposide cytotoxicity in HeLa cells. Cancer Res 1994; 54(18):4933-9.
38. Binder AB, Serafin AM, Bohm LJ, Abrogation of G(2)/M-phase block enhances the cytotoxicity of daunorubicin, melphalan and cisplatin in TP53 mutant human tumor cells. Radiat Res 2000; 154(6): 640-9.
39. Wong JS, Ara G, Keyes SR, Herbst R, Coleman CN, Teicher BA. Lisofylline as a modifier of radiation therapy. Oncol Res 1996; 8(12):513-8.
40. Husain A, Rosales N, Schwartz GK, Spriggs DR. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum (II). Gynecol Oncol 1998; 70(1):17-22.
41. Sarkaria JN, Eshleman JS. ATM as a target for novel radiosensitizers. Semin Radiat Oncol 2001; 11(4): 316-27.
42. Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 1993; 32(3): 183-9.
43. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ 1995; 6(8): 927-36.
44. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996; 88(14): 956-65.
45. Busby EC, Leistritz DF, Abraham RT, Kamitz LM, Sarkaria JN. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60(8):2108-12.
46. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275(8): 5600-5.
47. Bulavin DV, Amundson SA, Fornace AJ. p38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony. Curr Opin Genet Dev 2002; 12(1): 92-7.
48. Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000; 60(3): 566-72.
49. Syljuasen RG, Sorensen CS, Nylandsted J, Lukas C, Lukas J, Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res 2004; 64(24):9035-40.
50. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 2005; 25(9): 3553-62.
51. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55(11): 2325-33.
52. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta 2000; 1470(3): M79-91.
53. Altmann KH. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol 2001; 5(4): 424-31.
54. Jordan MA. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr Med Chem Anticancer Agents 2002; 2: 1-17.
55. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253-65.
56. Broker LE, Huisman C, Span SW, Rodriguez JA, Kruyt FA, Giaccone G. Cathepsin B mediates caspase-independent cell death induced by microtubule stabilizing agents in non-small cell lung cancer cells. Cancer Res 2004; 64(1): 27-30.
57. Broker LE, Huisman C, Ferreira CG, Rodriguez JA, Kruyt FA, Giaccone G. Late activation of apoptotic; pathways plays a negligible role in mediating the cytotoxic effects of discoderinolide and epothilone B in non-small cell lung cancer cells. Cancer Res 2002; 62(14):4081-8.
58. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22(56): 9075-86.
59. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78(4):539-42.
60. Sinc0lair WY, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966; 29(3):450-74.
61. Sinclair WK. Cyclic x-ray responses in mammalian cells in vitro. Radiat Res 1968; 33(3): 620-43.
62. Griffith TD, Tolmach LJ. Lethal response of HeLa cells to x-irradiation in the latter part of the generation cycle. Biophys J 1976; 16(4):303-18.
63. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59(4): 928-42.
64. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52(12): 3495-7.
65. Choy H. Taxanes in combined-modality therapy for solid tumors. Oncology (Williston Park) 1999; 13(10 Suppl 5): 23-38.
66. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994; 86(6): 441-6.
67. Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20(4 Suppl 3):1-15.
68. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332(15): 1004-14.
69. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997; 48: 353-74.
70. Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updat 2001; 4(6): 392-401.
71. Gerdi K, Bedorf N, Hofle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996; 49(6): 560-3.
72. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtabule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997; 272(4): 2534-41.
73. Ojima I, Chakravarty S, Inoue T, Lin S, He L, Horwitz SB, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Nad Acad Sci USA 1999; 96(8): 4256-61.
74. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Nad Acad Sci USA 2000; 97(6):2904-9.
75. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on alphabeta-tubulin by electron crystallography. Science 2004; 305(5685): 866-9.
76. Chou TC, Zhang XG, Harris CR, Kuduk SD, Balog A, Savin KA, et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proc Natl Acad Sci USA 1998; 95(26): 15798-802.
77. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2(1): 123-48.
78. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7(5): 1429-37.
79. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74(6): 957-67.
80. Hofstetter B, Vuong V, Broggini-Tenzer A, Bodis S, Ciernik IF, Fabbro D, et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005; 11(4):1588-96.
81. Hockel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and Radiation Response in Human Tumors. Semin Radiat Oncol 1996; 6(1): 3-9.
82. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OC. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26(312): 638-48.
83. Brown JM. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999; 59(23): 5863-70.
84. Overgaard J. Sensitization of hypoxic tumour cells--clinical experience. Int J Radiat Biol 1989; 56(5): 801-11.
85. Janssen HL, Haustermans KM, Balm AJ, Begg AC. Hypoxia in head and neck cancer: how much, how important? Head Neck 2005; 27(7): 622-38.
86. Fiedler W, Staib P, Kuse R, Duhrsen U, Flasshove M, Cavalli F, et al. Role of angiogenesis inhibitors in acute myeloid leukemia. Cancer J 2001; 7(Suppl 3): S129-33.
87. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.
88. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295(5559): 1526-8.
89. Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 2004; 7(4-5): 289-300.
90. Kerbel R, Folkman J. Clinical translation of arigiogenesis inhibitors. Nat Rev Cancer 2002; 2(10): 727-39.
91. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8(4): 299-309.
92. Moeller BJ, Cao Y, Vujaskovic Z, Li CY, Haroon ZA, Dewhirst MW. The relationship between hypoxia and angiogenesis. Semin Radiat Oncol 2004; 14(3): 215-21.
93. Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 1997; 37(5):1107-13.
94. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307(5706): 58-62.
95. Teicher BA, Holden SA, Ara G, Dupuis NP, Liu F, Yuan J, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 1995; 61(5):732-7.
96. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6(6): 553-63.
97. Matter A. Tumor angiogenesis as a therapeutic target. Drug Discov Today 2001; 6(19): 1005-1024.
98. Rosen LS. Angiogenesis inhibition in solid tumors. Cancer J 2001; 7(Suppl 3): S120-8.
99. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target Nature 2005; 438(7070): 967-74.
100. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 2003; 9(6):1957-71.
101. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394(6690): 287-91.
102. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001; 293(5528): 293-7.
103. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S, Beckett MA, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998; 58(24): 5686-9.
104. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59(14): 3374-8.
105. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001; 61(1): 3944.
106. Li J, Huang S, Armstrong EA, Fowler JF, Harari PM. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 2005; 62(5): 1477-85.
107. Fenton BM, Paoni SF, Ding I. Pathophysiological. effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on marine mammary tumors. Cancer Res 2004; 64(16): 5712-9.
108. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300(5622): 1155-9.
109. Zingg D, Riesterer O, Fabbro D, Glanzmann C, Bodis S, Pruschy M. Differential activation of the phosphatidylinositol. 3′-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells. Cancer Res 2004; 64(15): 5398-406.
110. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61(6): 2413-9.
111. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60(8): 2178-89.
112. Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and turnour growth. Br J Cancer 2001; 85(12): 2010-6.
113. Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, et al. Enhanced radiation damage of minor vasculature by mTOR inhibitors. Oncogene 2005; 24(35): 5414-22.
114. Camphausen K, Tofilon PJ. Combining radiation and molecular targeting in cancer therapy. Cancer Biol Ther 2004; 3(3): 247-50.
115. Ma BB, Bristow RG, Kim J, Siu LL. Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol 2003; 21(14): 2760-76.
116. Zips D, Hessel F, Krause M, Schiefer Y, Hoinkis C, Thames HD, et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005; 61(3): 908-14.
117. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford U, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004; 16(24): 8587-93.
118. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27(2): 131-46.
119. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987; 56: 881-914.
120. Hynes NE. Tyrosine kinase signalling in breast cancer. Breast Cancer Res 2000; 2(3): 154-7.
121. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77: 25-79.
122. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19(56): 6550-65.
123. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19(3): 183-232.
124. Alroy J, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997; 410(1): 83-6.
125. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidy-linositol-3-OH kinase signal transduction. Nature 1995; 376(6541): 599-602.
126. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 1999; 19(10): 6845-57.
127. Holbro T, Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 2004; 44: 195-217.
128. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5(5): 341-54.
129. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62(24): 7350-6.
130. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004; 58(2): 561-6.
131. Eicheler W, Krause M, Hessel F, Zips D, Baumann M. Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. Radiother Oncol 2005; 76(2): 151-6.
132. Goldkorn T, Balaban N, Shannon M, Matsukuma K. EGF receptor phosphorylation is affected by ionizing radiation. Biochim Biophys Acta 1997; 1358(3):289-99.
133. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, et al. Radiation-induced proliferation of the human A431 squarnous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Onoogene 1997; 15(10): 1191-7.
134. Denekamp J. Changes in the rate of repopulation during multifraction irradiation of mouse skin. Br J Radiol 1973; 46(545): 381-7.
135. Kavanagh BD, Lin PS, Chen P, Schmidt-Ullrich RK. Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor. Clin Cancer Res 1995; 1(12): 1557-62.
136. Krause M, Ostermann G, Petersen C, Yaromina A, Hessel F, Harstrick A, et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother Oncol 2005; 76(2): 162-7.
137. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998; 273(3): 1568-73.
138. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005; 280(35): 31182-9.
139. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6(6): 2166-74.
140. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005; 76(2): 157-61.
141. Gupta AK, Bakanauskas VJ, Cerniglia GJ, Cheng Y, Bernhard EJ, Muschel RJ, et al. The Ras radiation resistance pathway. Cancer Res 2001; 61(10):4278-82.
142. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, et al. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 2002; 8(3): 885-92.
143. Lammering G, Hewit TH, Hawkins WT, Contessa JN, Reardon DB, Lin PS, et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst 2001; 93(12): 921-9.
144. Lammering G, Valerie K, Lin PS, Mikkelsen RB, Contessa JN, Feden JP, et al. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res 2001; 7(3): 682-90.
145. Tenzer A, Zingg D, Rocha S, Hemmings B, Fabbro D, Glanzmann C, et al. The phosphatidylinositide 3′-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res 2001; 61(22): 8203-10.
146. Riesterer O, Tenzer A, Zingg D, Hofstetter B, Vuong V, Pruschy M, et al. Novel radiosensitizers for locally advanced epithelial tumors: inhibition of the P13K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy? Int J Radiat Oncol Biol Phys 2004; 58(2): 361-8.
147. Belka C, Jendrossek V, Pruschy M, Vink S, Verheij M, Budach W. Apoptosis-modulating agents in combination with radiotherapy-current status and outlook. Int J Radiat Oncol Biol Phys 2004; 58(2): 542-54.
148. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002; 62(15):4300-6.
149. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 2003; 55(3): 713-23.
150. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antiturnour therapy. Nature 1998; 394: 287-91.
151. Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, et al. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 2000; 6(5): 287-93.
152. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60(19): 5565-70.
153. Zips D, Krause M, Hessel F, Westphal J, Bruchner K, Eicheler W, et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and firactionated irradiation. Anticancer Res 2003; 23(5A): 3869-76.
154. Zips D, Eicheler W, Geyer P, Hessel F, Dorfler A, Thames HD, et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 2005; 65(12): 53 74-9.
155. Schuuring J, Bussink J, Bernsen HJ, Peeters W, van Der Kogel AJ. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 2005; 61(2): 529-34.
156. Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002; 157(1): 45-51.
157. Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003; 63(13):3755-63.
158. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005; 11(2 Pt 1): 743-50.
159. Liu W, Chen Y, Wang W, Keng P, Finkelstein J, Hu D, et al. Combination of radiation and celebrex (celecoxib) reduce mammary and lung tumor growth. Am J Clin Oncol 2003; 26(4): S103-9.
160. Dicker AP, Williams TL, Grant DS. Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 2001; 24(5): 438-42.
161. Kaliski A, Maggiorella L, Cengel KA, Mathe D, Rouffiac V, Opolon P, et al. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 2005; 4(11): 1717-28.
162. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. lot J Cancer 1994; 57(6):920-5.
163. Shintani S, Li C, Mihara M, Klosek SK, Terakado N, Hino S, et al. Anti-tumor effect of radiation response by combined treatment with angiogenesis inhibitor, TNP-470, in oral squamous cell carcinoma. Oral Oncol 2006; 42(1): 65-71.
164. Landuyt W, Ahmed B, Nuyts S, Theys J, Op de Beeck M, Rijnders A, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radial Oncol Biol Phys 2001; 49(2): 443-50.
165. Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, et al. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 2005; 11(15):5639-44.
166. Lu B, Geng L, Musiek A, Tan J, Cao C, Donnelly E, et al. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys 2004; 58(3): 844-50.
167. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002; 62(6): 1702-6.
168. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, et al. Trimodal cancer treatment: beneficial effects of combined anti-angiogenesis, radiation, and chemotherapy. Cancer Res 2005; 65(9): 3643-55.
169. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Damiano V, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Cho Cancer Res 2002; 8(10): 3250-8.
170. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA, Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002; 29(1 Suppl 4): 37-46.
171. Williams KJ, Telfer BA, Stratford U, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002; 86(7): 1157-61.
172. Shintani S, Kiyota A, Mihara M, Sumida T, Kayahara H, Nakashito K, et al. Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Am J Clin Oncol 2003; 26(5): e150-6.
173. Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 2003; 107(6):1030-7.
174. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, et al. Sequence-dependent effects of ZD1839 ('Iressa!) in combination with cytotoxic: treatment in human head and neck cancer. Br J Cancer 2002; 86(5): 819-27.
175. Burdak-Rothkamm S, Rube CE, Nguyen TP, Ludwig D, Feldmann K, Wiegel T, et al. Radiosensitivity of Tumor Cell Lines after Pretreatment with the EGFR Tyrosine Kinase Inhibitor ZD 1839 (Iressa((R))). Strahlenther Onkol 2005; 181(3): 197-204.
176. She Y, Lee F, Chen J, Haimovitz-Friedman A, Miller VA, Rusch VR, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 2003; 9(10 Pt 1): 3773-8.
177. Chinnaiyan P, Huang S, Vallabhaneni G. Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth fitctor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005; 65(8): 3328-35.
178. Baumann M, Krause M, Zips D, Eicheler W, Dorfler A, Ahrens J, et al. Selective inhibition of the epidermal growth factor receptor tyrosine kirum by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. Int J Radiat Biol 2003; 79(7): 547-59.
179. Toulany M. Dittmann K, Baumann M, Rodemann HP. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother Oncol 2005; 74(2):117-29.
180. Zhou H, Kim YS, Peletier A. McCall W, Earp HS, Sartor CI. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR-and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance. Int J Radiat Oncol Biol Phys 2004; 58(2): 344-52.
181. Murakami M, Sasaki T, Yamasaki S, Kuwahara K, Miyata H, Chayama K. Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT-1 cells. Biochem Biophys Res Commun 2004; 319(1):114-9.
182. Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM, et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 2004; 10(2): 691-700.
183. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 2000; 48(5): 1519-28.
184. Nakata E, Hunter N, Mason K, Fan Z, Ang KK, Milas L. C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chernoradiotherapy. Int J Radiat Oncol Biol Phys 2004; 59(4): 1163-73.
185. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 anti-epidermal growth factor receptor antibody. Clin Cancer Res 2000; 6(2): 701-8.
186. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radio-sensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59(8): 1935-40.
187. Nasu S, Ang KK, Fan Z, Milas L. C225 antiepidennal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001; 51(2): 474-7.
188. Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005; 11(2 Pt 1): 795-805.
189. Eller JL, Longo SL, Kyle MM, Bassano D, Hicklin DJ, Canute GW. Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in ghoblastoma, multiforme in vitro and in vivo. Neurosurgery 2005; 56(1): 155-62.
190. Sato S, Kajiyama Y, Sugano M, Iwanuma Y, Sonoue H, Matsumoto T, et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 2005; 61(1): 203-11.
191. Pommier Y, Sordet O, Rao VA, Zhang H, Kohn KW. Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 2005; 11(22): 2855-72.
192. Vaidyanathan G, Zalutsky MR. Imaging drug resistance with radio-labeled molecules. Curr Pharm, Des 2004; 10(24): 2965-79.
193. Wu X, Kbalpey Z, Cascalho M. Cellular physiology of mismatch repair. Curr Pharm Des 2004; 10(32): 4121-6.